Table II. Pairwise analysis of mAbs in passive protection studies
PH12TB12LE4CH1SWB1PA16C4WECH1SyH7
TB121.00000a
LE40.93744a0.93744a
CH10.014680.014680.00528
SWB10.018910.018910.043410.23219
PA10.001950.001950.000940.937440.10706
6C40.000200.000201.8 × 10−51.8 × 10−50.000870.00016
WECH10.002280.002280.001490.464080.299470.650941.80 × 10−5
SyH70.000670.000670.001490.361370.321400.232580.000200.71816
b0.000200.000201.8 × 10−51.8 × 10−50.000670.00015(0.0339)c1.8 × 10−50.00020
  • Survival analysis between groups using pairwise comparisons with the log-rank test. The p values were adjusted for multiple testing with the Benjamini–Hochberg procedure.

  • a The three MAbs (TB12, PH12, and LE4) were not significantly different from each other in the protection assay but were more effective in vivo than the other six mAbs tested, as noted by the boldface text.

  • b Dash (—) indicates control mice that received ricin only.

  • c Parentheses indicate that mice treated with 6C4 died significantly earlier than control mice.